Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

Dimerix Limited

DXB.AXASX
Healthcare
Biotechnology
$0.35
$-0.02(-5.41%)
Australian Market opens in 5h 46m

Dimerix Limited Fundamental Analysis

Dimerix Limited (DXB.AX) shows moderate financial fundamentals with a PE ratio of -12.88, profit margin of -2.20%, and ROE of -2.79%. The company generates $0.0B in annual revenue with strong year-over-year growth of 14.86%.

Key Strengths

Cash Position18.32%
PEG Ratio0.93
Current Ratio3.15

Areas of Concern

ROE-2.79%
Operating Margin-5.48%
We analyze DXB.AX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -398.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-398.7/100

We analyze DXB.AX's fundamental strength across five key dimensions:

Efficiency Score

Weak

DXB.AX struggles to generate sufficient returns from assets.

ROA > 10%
-25.26%

Valuation Score

Excellent

DXB.AX trades at attractive valuation levels.

PE < 25
-12.88
PEG Ratio < 2
0.93

Growth Score

Excellent

DXB.AX delivers strong and consistent growth momentum.

Revenue Growth > 5%
14.86%
EPS Growth > 10%
11.08%

Financial Health Score

Excellent

DXB.AX maintains a strong and stable balance sheet.

Debt/Equity < 1
-0.02
Current Ratio > 1
3.15

Profitability Score

Weak

DXB.AX struggles to sustain strong margins.

ROE > 15%
-278.87%
Net Margin ≥ 15%
-2.20%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is DXB.AX Expensive or Cheap?

P/E Ratio

DXB.AX trades at -12.88 times earnings. This suggests potential undervaluation.

-12.88

PEG Ratio

When adjusting for growth, DXB.AX's PEG of 0.93 indicates potential undervaluation.

0.93

Price to Book

The market values Dimerix Limited at -124.97 times its book value. This may indicate undervaluation.

-124.97

EV/EBITDA

Enterprise value stands at -6.17 times EBITDA. This is generally considered low.

-6.17

How Well Does DXB.AX Make Money?

Net Profit Margin

For every $100 in sales, Dimerix Limited keeps $-2.20 as profit after all expenses.

-2.20%

Operating Margin

Core operations generate -5.48 in profit for every $100 in revenue, before interest and taxes.

-5.48%

ROE

Management delivers $-2.79 in profit for every $100 of shareholder equity.

-2.79%

ROA

Dimerix Limited generates $-25.26 in profit for every $100 in assets, demonstrating efficient asset deployment.

-25.26%

Following the Money - Real Cash Generation

Operating Cash Flow

Dimerix Limited generates strong operating cash flow of $11.45M, reflecting robust business health.

$11.45M

Free Cash Flow

Dimerix Limited generates strong free cash flow of $11.43M, providing ample flexibility for dividends, buybacks, or growth.

$11.43M

FCF Per Share

Each share generates $0.02 in free cash annually.

$0.02

FCF Yield

DXB.AX converts 5.44% of its market value into free cash.

5.44%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-12.88

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.93

vs 25 benchmark

P/B Ratio

Price to book value ratio

-124.97

vs 25 benchmark

P/S Ratio

Price to sales ratio

28.34

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-0.02

vs 25 benchmark

Current Ratio

Current assets to current liabilities

3.15

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-2.79

vs 25 benchmark

ROA

Return on assets percentage

-0.25

vs 25 benchmark

ROCE

Return on capital employed

-0.78

vs 25 benchmark

How DXB.AX Stacks Against Its Sector Peers

MetricDXB.AX ValueSector AveragePerformance
P/E Ratio-12.8828.25 Better (Cheaper)
ROE-278.87%780.00% Weak
Net Margin-219.94%-20122.00% (disorted) Weak
Debt/Equity-0.020.30 Strong (Low Leverage)
Current Ratio3.154.66 Strong Liquidity
ROA-25.26%-14687.00% (disorted) Weak

DXB.AX outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Dimerix Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-85.63%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-110.88%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

9.25%

Industry Style: Defensive, Growth, Innovation

Growing

Fundamental Analysis FAQ